Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBITDA Margin (2016 - 2025)

Vistagen Therapeutics' EBITDA Margin history spans 12 years, with the latest figure at 6237.62% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 21198.0% year-over-year to 6237.62%; the TTM value through Dec 2025 reached 8486.58%, down 171399.0%, while the annual FY2025 figure was 10578.81%, 781922.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 6237.62% at Vistagen Therapeutics, up from 7520.93% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 90940.0% in Q1 2025 and bottomed at 12775.0% in Q2 2024.
  • The 4-year median for EBITDA Margin is 3575.42% (2021), against an average of 1520.98%.
  • The largest annual shift saw EBITDA Margin tumbled -932350bps in 2024 before it surged 9576565bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 2943.85% in 2021, then surged by 48bps to 1545.01% in 2023, then tumbled by -290bps to 6025.64% in 2024, then dropped by -4bps to 6237.62% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EBITDA Margin are 6237.62% (Q4 2025), 7520.93% (Q3 2025), and 6188.11% (Q2 2025).